Clinical trials: Recurrent Glioblastoma Multiforme
Glioblastoma Multiforme, Anaplastic Astrocytoma
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
This study will offer a safe treatment for patients with relapsing recurring glioblastoma (GBM) or anaplastic astrocytoma (AA). The trial will test the hypothesis that Erlotinib (Tarceva, OSI-774) can be safely used up to a dose…
- Trial name
- NCT00301418
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Glioma Tumor Recurrence, Radiation Necrosis
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis
This study will examine the use of a variation of standard magnetic resonance imaging (MRI) called diffusion tensor MRI (DT-MRI) for distinguishing injured brain tissue due to radiation therapy (radiation necrosis) from the…
- Conditions
- Glioma Tumor Recurrence, Radiation Necrosis, Primary Brain Tumor
- Trial name
- NCT00285324
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioblastoma Multiforme
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
A Phase II, multi-center, open-label, single-arm study in up to 42 subjects with first recurrence or progression of GBM at up to 12 sites in Australia, Europe, Israel, and the United States.
- Trial name
- CLARITY-1 (NCT00797940)
- Testing
- IL-4PE
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sophiris Bio Corp
Glioblastoma
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
- Trial name
- NCT05700955
- Testing
- Pembrolizumab and Temozolomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Glioblastoma, Gliosarcoma
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)
Primary objective: To evaluate activity of imatinib mesylate and hydroxyurea among patients with progressive/recurrent grade II low-grade glioma (LGG) as measured by 12-month progression free survival Secondary objectives: To…
- Trial name
- NCT00615927
- Testing
- Imatinib Mesylate & Hydroxyurea
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Duke University
Healthy Subject, Intracranial Neoplasm
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
This phase I trial studies how well [18F]DASA-23 and positron emission tomography (PET) scan work in evaluating pyruvate kinase M2 (PKM2) expression in patients with intracranial tumors or recurrent glioblastoma and healthy…
- Conditions
- Healthy Subject, Intracranial Neoplasm, Glioblastoma
- Trial name
- NCT03539731
- Testing
- Fluorine F 18 DASA-23, Positron Emission Tomography
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Guido A. Davidzon, MD, SM